A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
While Cogent joins the FGFR party.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Just when investors thought things couldn't get any worse, they do.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
